Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
Intrinsic Value
Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. [ Read More ]
The intrinsic value of one
Jiangsu Bioperfectus Technologies Co Ltd
stock under the Base Case scenario is
1 747.79
CNY.
Compared to the current market price of 65.01 CNY,
Jiangsu Bioperfectus Technologies Co Ltd
is
Undervalued by 96%.
Jiangsu Bioperfectus Technologies Co Ltd's market capitalization is 3.8B CNY.
Jiangsu Bioperfectus Technologies Co Ltd stock price is 65.01 CNY.
Jiangsu Bioperfectus Technologies Co Ltd stock price (65.01 CNY) is 96% less than its Intrinsic Value (1 747.79 CNY).
Jiangsu Bioperfectus Technologies Co Ltd stock price (65.01 CNY) is 98% less than its DCF Value (3 466.93 CNY). Open DCF Valuation
Jiangsu Bioperfectus Technologies Co Ltd stock (28.65 CNY) is 56% less than its price (65.01 CNY). Open Relative Valuation
Jiangsu Bioperfectus Technologies Co Ltd.
Jiangsu Bioperfectus Technologies Co Ltd's Revenue has been growing by 8% per year for the last 3 years.
Jiangsu Bioperfectus Technologies Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 1%.
Jiangsu Bioperfectus Technologies Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 0%.
Jiangsu Bioperfectus Technologies Co Ltd's Revenue has dropped by 69% over the past 12 months.
Jiangsu Bioperfectus Technologies Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 69% to 1%.
Jiangsu Bioperfectus Technologies Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 144% to 0%.
Jiangsu Bioperfectus Technologies Co Ltd has positive Net Income for the last twelve months.
Jiangsu Bioperfectus Technologies Co Ltd has positive Operating Income for the last twelve months.
Jiangsu Bioperfectus Technologies Co Ltd has positive Gross Profit for the last twelve months.
Jiangsu Bioperfectus Technologies Co Ltd has positive Free Cash Flow for the last twelve months.
Jiangsu Bioperfectus Technologies Co Ltd's Altman Z-Score is very high and is equal to 3.98.
Jiangsu Bioperfectus Technologies Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.09.
Jiangsu Bioperfectus Technologies Co Ltd has very high three-year average ROE (Return on Equity): 53%. The company is very efficient at transforming stockholders' equity into net income.
Jiangsu Bioperfectus Technologies Co Ltd has very high three-year average ROIC (Return on Invested Capital): 99%. The company is very efficient at using invested capital to generate operating income.
Jiangsu Bioperfectus Technologies Co Ltd's short-term assets (3B CNY) exceed its short-term liabilties (502m CNY).
Jiangsu Bioperfectus Technologies Co Ltd's long-term assets (4B CNY) exceed its long-term liabilties (683m CNY).
Jiangsu Bioperfectus Technologies Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (3B CNY) than debt (332m CNY).
Fundamental Analysis
Jiangsu Bioperfectus Technologies Co Ltd
Balance Sheet Decomposition
Jiangsu Bioperfectus Technologies Co Ltd
| Current Assets | 3B |
| Cash & Short-Term Investments | 2.5B |
| Receivables | 262.8m |
| Other Current Assets | 228m |
| Non-Current Assets | 1.3B |
| Long-Term Investments | 358.2m |
| PP&E | 732.8m |
| Intangibles | 26.5m |
| Other Non-Current Assets | 132.8m |
| Current Liabilities | 501.7m |
| Accounts Payable | 88.9m |
| Accrued Liabilities | 24.6m |
| Short-Term Debt | 297.1m |
| Other Current Liabilities | 91.2m |
| Non-Current Liabilities | 181.5m |
| Long-Term Debt | 35m |
| Other Non-Current Liabilities | 146.6m |
Earnings Waterfall
Jiangsu Bioperfectus Technologies Co Ltd
|
Revenue
|
1.5B
CNY
|
|
Cost of Revenue
|
-612.6m
CNY
|
|
Gross Profit
|
905.1m
CNY
|
|
Operating Expenses
|
-901.7m
CNY
|
|
Operating Income
|
3.5m
CNY
|
|
Other Expenses
|
24.1m
CNY
|
|
Net Income
|
27.5m
CNY
|
Free Cash Flow Analysis
Jiangsu Bioperfectus Technologies Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Jiangsu Bioperfectus Technologies Co Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Jiangsu Bioperfectus Technologies Co Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Jiangsu Bioperfectus Technologies Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Jiangsu Bioperfectus Technologies Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Jiangsu Bioperfectus Technologies Co Ltd
Shareholder Return
Price
Jiangsu Bioperfectus Technologies Co Ltd
| Average Annual Return | 45.58% |
| Standard Deviation of Annual Returns | 127.62% |
| Max Drawdown | -89% |
| Market Capitalization | 3.8B CNY |
| Shares Outstanding | 58 620 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jiangsu Bioperfectus Technologies Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu and currently employs 765 full-time employees. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.
You don't have any saved screeners yet
